遺伝性血管性浮腫（HAE）治療の世界市場規模調査＆予測：薬剤クラス別、治療タイプ別、投与経路別、地域別分析、2023-2030年

世界の遺伝性血管性浮腫（HAE）治療市場は、2022年に約44億2,000万米ドルと評価され、予測期間2023-2030年には8.5％以上の健全な成長率で成長すると予測されています。

遺伝性血管性浮腫（HAE）は、顔、喉、手足、腹部など身体の様々な部位に腫脹の再発を引き起こすまれな遺伝性疾患です。これらの発作は重篤で、気道が侵されると生命を脅かすことがあります。遺伝性血管性浮腫（HAE）治療市場は、遺伝性疾患の有病率の上昇や新規治療薬の採用増加などの要因により拡大しています。アンドロゲンは、C1阻害剤の産生を増加させ、HAE発作の頻度と重症度を減少させることができるホルモンです。しかし、女性や小児の男性化、肝毒性、血栓リスクの増加などの重大な副作用があります。HAEの有病率はここ数十年の間に徐々に増加しています。

世界保健機関（WHO）によると、遺伝性疾患や先天性異常は出生児の約2％～5％にみられ、小児科入院の最大30％を占め、先進国では小児死亡の約50％を引き起こしています。さらに、Statistaによると、2020年に欧州が実施した調査では、英国の回答者の36％が、遺伝性疾患への傾向において遺伝が果たす重要性を認識していないことが判明しました。この分野を牽引するもう一つの重要な要素は、新規治療薬の採用が増加していることです。Statistaによると、世界で最も支出されると予測される治療分野は腫瘍学で約3,770億米ドル、次いで免疫学が約1,770億米ドルで2位と予測されています。さらに2022年、Wave Life Sciences Ltdは、Waveの前臨床RNA編集プログラムを含むオリゴヌクレオチド治療薬を前進させる戦略的提携を行っています。この探索共同研究の最初の調査期間は4年間です。GSKのユニークなヒト遺伝学的洞察力と世界な開発・商業能力は、Waveの特許取得済みの創薬・医薬品開発プラットフォームであるPRISMTMと組み合わされます。また、血管性浮腫に関連する薬剤の製剤化と技術的進歩は、予測期間中、市場に有利な成長見通しを生み出すと思われます。しかし、遺伝性血管性浮腫（HAE）治療に対する認識不足が、2023-2030年の予測期間を通じて市場の成長を阻害しています。

遺伝性血管性浮腫（HAE）治療の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、同地域の主要市場プレイヤーの存在により、2022年の市場を独占しました。Statistaによると、北米は2020年に世界の細胞・遺伝子治療産業の約56%を占め、2021年から2027年にかけて33.8%の割合で増加すると予想されています。アジア太平洋地域は、老年人口や対象人口の増加、政府機関や非営利団体の積極的な市場参入などの要因により、予測期間中に大きく成長すると予想されています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

• 市場スナップショット
• 世界市場・セグメント別市場推計・予測、2020-2030年
  • 遺伝性血管性浮腫（HAE）治療市場：地域別、2020-2030年
  • 遺伝性血管性浮腫（HAE）治療市場：薬剤クラス別、2020-2030年
  • 遺伝性血管性浮腫（HAE）治療市場：治療タイプ別、2020-2030年
  • 遺伝性血管性浮腫（HAE）治療市場：投与経路別、2020-2030年
• 主要動向
• 調査手法
• 調査前提条件

第2章 遺伝性血管性浮腫（HAE）治療の世界市場定義とスコープ

• 調査目的
• 市場の定義と範囲
  • 産業の発展
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 遺伝性血管性浮腫（HAE）治療の世界市場力学

• 遺伝性血管性浮腫（HAE）治療市場の影響分析（2020-2030年）
  • 市場促進要因
    • 遺伝性疾患の有病率の上昇
    • 新規治療薬の採用増加
  • 市場の課題
    • 遺伝性血管性浮腫（HAE）治療に対する認識不足
  • 市場機会
    • 製剤の進歩
    • 血管性浮腫治療薬の技術進歩

第4章 世界の遺伝性血管性浮腫（HAE）治療市場の産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォース影響分析
• PEST分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 遺伝性血管性浮腫（HAE）治療の世界市場：薬剤クラス別

• 市場スナップショット
• 遺伝性血管性浮腫（HAE）治療の世界市場：薬剤クラス別、業績-潜在能力分析
• 遺伝性血管性浮腫（HAE）治療の世界市場：薬剤クラス別推定・予測2020-2030年
• 遺伝性血管性浮腫（HAE）治療市場、サブセグメント分析
  • C1-エステラーゼ阻害薬
  • ブラジキニンB2受容体拮抗薬
  • カリクレイン阻害薬
  • その他

第6章 遺伝性血管性浮腫（HAE）治療の世界市場：治療タイプ別

• 市場スナップショット
• 遺伝性血管性浮腫（HAE）治療の世界市場：治療タイプ別、業績-潜在能力分析
• 遺伝性血管性浮腫（HAE）治療の世界市場：治療タイプ別推定・予測2020-2030年
• 遺伝性血管性浮腫（HAE）治療市場、サブセグメント別分析
  • 予防
  • オンデマンド

第7章 遺伝性血管性浮腫（HAE）治療の世界市場：投与経路別

• 市場スナップショット
• 遺伝性血管性浮腫（HAE）治療の世界市場：投与経路別、業績-潜在能力分析
• 遺伝性血管性浮腫（HAE）治療の世界市場、投与経路別推定・予測2020-2030年
• 遺伝性血管性浮腫（HAE）治療市場、サブセグメント分析
  • 静脈内投与
  • 皮下投与
  • 経口

第8章 遺伝性血管性浮腫（HAE）治療の世界市場：地域別分析

• 主要国
• 新興国
• 遺伝性血管性浮腫（HAE）治療市場、地域別市場スナップショット
• 北米
  • 米国
    • 薬剤クラスの推定・予測、2020-2030年
    • 治療タイプ別の推定・予測、2020-2030年
    • 投与経路別の推定・予測、2020～2030年
  • カナダ
• 欧州の遺伝性血管性浮腫（HAE）治療市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋の遺伝性血管性浮腫（HAE）治療市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの遺伝性血管性浮腫（HAE）治療市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他中東とアフリカ

第9章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • CSL Limited
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
    • 最近の動向
  • Takeda Pharmaceutical Company Limited
  • Pharming Healthcare Inc
  • Sanofi S.A.
  • BioCryst Pharmaceuticals Inc
  • Ionis Pharmaceuticals, Inc
  • Shire Plc
  • Attune Pharmaceuticals, Inc
  • Adverum Biotechnologies, Inc
  • KalVista Pharmaceuticals, Inc

第10章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Hereditary Angioedema Therapeutic Market, report scope
• TABLE 2. Global Hereditary Angioedema Therapeutic Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Hereditary Angioedema Therapeutic Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
• TABLE 4. Global Hereditary Angioedema Therapeutic Market estimates & forecasts by Treatment Type 2020-2030 (USD Billion)
• TABLE 5. Global Hereditary Angioedema Therapeutic Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
• TABLE 6. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Hereditary Angioedema Therapeutic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. Global Hereditary Angioedema Therapeutic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17. U.S. Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. U.S. Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19. Canada Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 20. Canada Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. Canada Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22. UK Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 23. UK Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. UK Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25. Germany Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 26. Germany Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. Germany Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28. France Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 29. France Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. France Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31. Italy Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 32. Italy Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Italy Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34. Spain Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 35. Spain Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. Spain Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37. RoE Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 38. RoE Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. RoE Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40. China Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 41. China Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. China Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43. India Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 44. India Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. India Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46. Japan Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 47. Japan Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. Japan Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49. South Korea Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 50. South Korea Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. South Korea Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52. Australia Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 53. Australia Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. Australia Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. RoAPAC Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58. Brazil Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 59. Brazil Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Brazil Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61. Mexico Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 62. Mexico Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. Mexico Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64. RoLA Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 65. RoLA Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. RoLA Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67. Saudi Arabia Hereditary Angioedema Therapeutic Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 68. South Africa Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. RoMEA Hereditary Angioedema Therapeutic Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Hereditary Angioedema Therapeutic Market
• TABLE 71. List of primary sources, used in the study of global Hereditary Angioedema Therapeutic Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Hereditary Angioedema Therapeutic Market, research methodology
• FIG 2. Global Hereditary Angioedema Therapeutic Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Hereditary Angioedema Therapeutic Market, key trends 2022
• FIG 5. Global Hereditary Angioedema Therapeutic Market, growth prospects 2023-2030
• FIG 6. Global Hereditary Angioedema Therapeutic Market, porters 5 force model
• FIG 7. Global Hereditary Angioedema Therapeutic Market, pest analysis
• FIG 8. Global Hereditary Angioedema Therapeutic Market, value chain analysis
• FIG 9. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Hereditary Angioedema Therapeutic Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Hereditary Angioedema Therapeutic Market, regional snapshot 2020 & 2030
• FIG 15. North America Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)
• FIG 17. Asia Pacific Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Hereditary Angioedema Therapeutic Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Hereditary Angioedema Therapeutic Market is valued at approximately USD 4.42 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period 2023-2030. Hereditary angioedema is a rare genetic disorder that causes recurrent episodes of swelling in various parts of the body, including the face, throat, limbs, and abdomen. These attacks can be severe and life-threatening if they involve the airway. The Hereditary Angioedema Therapeutic market is expanding because of factors such as rising prevalence of genetic disorders and increasing adoption of novel therapeutics. Androgens are hormones that can increase the production of C1 inhibitors and reduce the frequency and severity of HAE attacks. However, they have significant side effects, including masculinization in women and children, liver toxicity, and an increased risk of blood clots. Its prevalence has progressively increased during the last few decades.

According to the World Health Organization, Genetic disorders and congenital abnormalities occur in about 2%-5% of all live births, accounting for up to 30% of pediatric hospital admissions, and cause about 50% of childhood deaths in industrialized countries. Furthermore, as per Statista, in 2020 Europe conducted a survey and found that 36% of respondents in the United Kingdom were unaware of the significance heredity plays in a person's proclivity to hereditary disorders. Another important component driving space is increasing adoption of novel therapeutics. According to Statista, the top therapy areas worldwide is projected to spend on is about USD 377 billion on oncology followed by immunology is projected to be second with around USD 177 billion of spending. In addition, in 2022, Wave Life Sciences Ltd had a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program. The initial research duration for the discovery collaboration is four years. GSK's unique human genetic insights, as well as its global development and commercial capabilities, are combined with Wave's patented discovery and medication development platform, PRISMTM. Also, advancements in formulation and technological advancement in drugs related to angioedema would create a lucrative growth prospectus for the market over the forecast period. However, lack of awareness about hereditary angioedema therapeutics stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Hereditary Angioedema Therapeutic Market study include: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players in the region. According to Statista, North America dominated the worldwide cell and gene therapy industry in 2020, accounting for about 56% of the total market and expected to increase at a rate of 33.8% between 2021 and 2027. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric and target populations, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

• CSL Limited
• Takeda Pharmaceutical Company Limited
• Pharming Healthcare Inc
• Sanofi S.A.
• BioCryst Pharmaceuticals Inc
• Ionis Pharmaceuticals, Inc
• Shire Plc
• Attune Pharmaceuticals, Inc
• Adverum Biotechnologies, Inc
• KalVista Pharmaceuticals, Inc

Recent Developments in the Market:

• In March 2023, Sanofi SA intended to pay $2.9 billion for Provention Bio Inc in order to boost its therapeutic pipeline. Sanofi would get complete ownership of Tzield, a medicine that was authorized in the United States for delaying the onset of type 1 diabetes's third and final stage.

Global Hereditary Angioedema Therapeutic Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Drug Class, Treatment Type, Route of Administration, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Class

• C1-esterase inhibitor
• Bradykinin B2 receptor antagonist
• Kallikrein inhibitor
• Others

By Treatment Type

• Prophylaxis
• On-demand

By Route of Administration

• Intravenous
• Subcutaneous
• Oral

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Hereditary Angioedema Therapeutic Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Hereditary Angioedema Therapeutic Market, by Drug Class, 2020-2030 (USD Billion)
  • 1.2.3. Hereditary Angioedema Therapeutic Market, by Treatment Type, 2020-2030 (USD Billion)
  • 1.2.4. Hereditary Angioedema Therapeutic Market, by Route of Administration, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Hereditary Angioedema Therapeutic Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Hereditary Angioedema Therapeutic Market Dynamics

• 3.1. Hereditary Angioedema Therapeutic Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising prevalence of genetic disorders
    • 3.1.1.2. Increasing adoption of novel therapeutics
  • 3.1.2. Market Challenges
    • 3.1.2.1. Lack of awareness about Hereditary Angioedema Therapeutic
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Advancements in Formulation
    • 3.1.3.2. Technological advancement in drugs related to Angioedema

Chapter 4. Global Hereditary Angioedema Therapeutic Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Hereditary Angioedema Therapeutic Market, by Drug Class

• 5.1. Market Snapshot
• 5.2. Global Hereditary Angioedema Therapeutic Market by Drug Class, Performance - Potential Analysis
• 5.3. Global Hereditary Angioedema Therapeutic Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
• 5.4. Hereditary Angioedema Therapeutic Market, Sub Segment Analysis
  • 5.4.1. C1-esterase inhibitor
  • 5.4.2. Bradykinin B2 receptor antagonist
  • 5.4.3. Kallikrein inhibitor
  • 5.4.4. Others

Chapter 6. Global Hereditary Angioedema Therapeutic Market, by Treatment Type

• 6.1. Market Snapshot
• 6.2. Global Hereditary Angioedema Therapeutic Market by Treatment Type, Performance - Potential Analysis
• 6.3. Global Hereditary Angioedema Therapeutic Market Estimates & Forecasts by Treatment Type 2020-2030 (USD Billion)
• 6.4. Hereditary Angioedema Therapeutic Market, Sub Segment Analysis
  • 6.4.1. Prophylaxis
  • 6.4.2. On-demand

Chapter 7. Global Hereditary Angioedema Therapeutic Market, by Route of Administration

• 7.1. Market Snapshot
• 7.2. Global Hereditary Angioedema Therapeutic Market by Route of Administration, Performance - Potential Analysis
• 7.3. Global Hereditary Angioedema Therapeutic Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 7.4. Hereditary Angioedema Therapeutic Market, Sub Segment Analysis
  • 7.4.1. Intravenous
  • 7.4.2. Subcutaneous
  • 7.4.3. Oral

Chapter 8. Global Hereditary Angioedema Therapeutic Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Hereditary Angioedema Therapeutic Market, Regional Market Snapshot
• 8.4. North America Hereditary Angioedema Therapeutic Market
  • 8.4.1. U.S. Hereditary Angioedema Therapeutic Market
    • 8.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Treatment Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Route of Administration breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Hereditary Angioedema Therapeutic Market
• 8.5. Europe Hereditary Angioedema Therapeutic Market Snapshot
  • 8.5.1. U.K. Hereditary Angioedema Therapeutic Market
  • 8.5.2. Germany Hereditary Angioedema Therapeutic Market
  • 8.5.3. France Hereditary Angioedema Therapeutic Market
  • 8.5.4. Spain Hereditary Angioedema Therapeutic Market
  • 8.5.5. Italy Hereditary Angioedema Therapeutic Market
  • 8.5.6. Rest of Europe Hereditary Angioedema Therapeutic Market
• 8.6. Asia-Pacific Hereditary Angioedema Therapeutic Market Snapshot
  • 8.6.1. China Hereditary Angioedema Therapeutic Market
  • 8.6.2. India Hereditary Angioedema Therapeutic Market
  • 8.6.3. Japan Hereditary Angioedema Therapeutic Market
  • 8.6.4. Australia Hereditary Angioedema Therapeutic Market
  • 8.6.5. South Korea Hereditary Angioedema Therapeutic Market
  • 8.6.6. Rest of Asia Pacific Hereditary Angioedema Therapeutic Market
• 8.7. Latin America Hereditary Angioedema Therapeutic Market Snapshot
  • 8.7.1. Brazil Hereditary Angioedema Therapeutic Market
  • 8.7.2. Mexico Hereditary Angioedema Therapeutic Market
• 8.8. Middle East & Africa Hereditary Angioedema Therapeutic Market
  • 8.8.1. Saudi Arabia Hereditary Angioedema Therapeutic Market
  • 8.8.2. South Africa Hereditary Angioedema Therapeutic Market
  • 8.8.3. Rest of Middle East & Africa Hereditary Angioedema Therapeutic Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. CSL Limited
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Takeda Pharmaceutical Company Limited
  • 9.3.3. Pharming Healthcare Inc
  • 9.3.4. Sanofi S.A.
  • 9.3.5. BioCryst Pharmaceuticals Inc
  • 9.3.6. Ionis Pharmaceuticals, Inc
  • 9.3.7. Shire Plc
  • 9.3.8. Attune Pharmaceuticals, Inc
  • 9.3.9. Adverum Biotechnologies, Inc
  • 9.3.10. KalVista Pharmaceuticals, Inc

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption